Rhabdomyosarcoma is the most common soft tissue sarcoma in children, arising from cells that were supposed to become skeletal muscle but stalled partway through their development and began growing out of control. It can appear almost anywhere in the body, including the head and neck, the urinary tract, the limbs, and the trunk. The biology behind this cancer, and the outlook for someone diagnosed with it, depends heavily on a few molecular details that have reshaped how doctors classify and treat it over the past two decades.
What Rhabdomyosarcoma Actually Is
At its core, rhabdomyosarcoma (RMS) is a tumor of immature muscle cells. Normal muscle development requires precursor cells called myoblasts to multiply, then stop dividing and fuse together into mature muscle fibers. In RMS, that process breaks down. The tumor cells commit to the muscle lineage and begin expressing muscle-related proteins, but they never finish maturing. They get stuck in a state where they keep dividing instead of becoming functional muscle tissue.1PubMed. Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells Both major subtypes express muscle-specific markers like MyoD, yet their ability to complete differentiation is impaired.2PubMed Central. Mechanisms of impaired differentiation in rhabdomyosarcoma
Research into one subtype, embryonal RMS, has shown that a signaling pathway involving a receptor called RAGE is abnormally low or absent in these tumor cells. Without RAGE signaling, a transcription factor called PAX7 accumulates to high levels. PAX7 normally marks muscle stem cells and needs to be turned down for those cells to mature. When it stays elevated, it promotes ongoing cell division and suppresses the proteins needed for muscle differentiation, creating a feedback loop that fuels uncontrolled growth.3Journal of Cell Science. RAGE signaling deficiency in rhabdomyosarcoma cells causes upregulation of PAX7 and uncontrolled proliferation
The Four Recognized Subtypes
The World Health Organization currently classifies RMS into four subtypes based on how the tumor looks under a microscope and what genetic abnormalities it carries: embryonal, alveolar, spindle cell/sclerosing, and pleomorphic.4PubMed. Rhabdomyosarcoma: Updates on classification and the necessity of molecular testing beyond immunohistochemistry Each has a distinct pattern of behavior.
- Embryonal: The most common subtype in children, typically appearing in the head, neck, or genitourinary tract. It tends to carry a more favorable prognosis, especially when localized.
- Alveolar: Named for its resemblance to lung air sacs under the microscope. This subtype is more aggressive and strongly associated with specific chromosomal rearrangements involving the FOXO1 gene.
- Spindle cell/sclerosing: A less common variant that can behave quite differently depending on its molecular features.
- Pleomorphic: Primarily seen in adults rather than children. It is rare in pediatric patients and generally carries a poor prognosis.
These subtypes show distinctive morphology and characteristic genetic abnormalities, making molecular testing increasingly central to diagnosis.5PubMed Central. Evolving classification of rhabdomyosarcoma The field has been shifting toward defining RMS less by what it looks like and more by what is happening in its DNA, because the molecular profile often predicts outcomes more accurately than microscopic appearance alone.
Fusion Status and Why It Matters So Much
The single most consequential molecular feature in RMS is whether the tumor carries a specific chromosomal rearrangement that fuses part of the PAX3 or PAX7 gene to the FOXO1 gene. This creates an abnormal “fusion protein” that drives tumor growth. Cases with this rearrangement are called fusion-positive, and those without it are fusion-negative. The distinction increasingly overshadows the traditional histological subtypes in clinical decision-making.
Among alveolar RMS patients tracked through the French National Childhood Cancer Registry, roughly 61% had PAX3-FOXO1 fusions, 15% had PAX7-FOXO1, and about 7% were fusion-negative despite having alveolar histology.6PubMed. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features The PAX3-FOXO1 fusion carries a worse prognosis than PAX7-FOXO1. Patients with PAX3-FOXO1 tumors were more likely to be older at diagnosis and to have metastatic disease at presentation. After adjusting for disease stage, those with PAX3-FOXO1 were roughly 3.6 times more likely to die than those with PAX7-FOXO1.
Fusion-negative RMS, which includes most embryonal cases, has a different genetic landscape. More than half of fusion-negative tumors carry mutations in one or more members of the RAS signaling pathway, a well-known cancer growth driver. A large international genomic study also found higher-than-expected rates of mutations in BCOR, NF1, and TP53, with TP53 mutations linked to worse outcomes regardless of fusion status.7PubMed Central. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium About a fifth of fusion-negative cases had no identifiable driver mutation at all, which complicates efforts to develop targeted therapies for this group.8PubMed Central. Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma
Children’s Oncology Group analyses have confirmed that incorporating FOXO1 fusion status into risk stratification, alongside traditional factors like tumor location, size, and whether the disease has spread, improves the ability to predict who will do well and who needs more intensive treatment.9Journal of Clinical Oncology. Risk stratification including FOXO1 fusion status (FOXO1) in patients with rhabdomyosarcoma (RMS) treated on six recent frontline trials: A report from the Children’s Oncology Group (COG)
How Rhabdomyosarcoma Is Diagnosed
A tissue biopsy is essential. RMS can mimic other small round blue cell tumors under the microscope, so pathologists rely on a panel of immunohistochemical stains to confirm muscle lineage. Desmin, a protein found in muscle cells, is one of the most reliable markers. Studies have shown that desmin staining is positive in the overwhelming majority of RMS cells and yields very few false positives or negatives, making it a strong tool for separating RMS from look-alike tumors.10PubMed Central. Desmin is a specific marker for rhabdomyosarcomas of human and rat origin
Diagnosis can get tricky with the alveolar subtype, which sometimes expresses markers you would not expect in a muscle tumor. About half of alveolar RMS cases stain positive for cytokeratins (typically associated with epithelial cancers), and roughly a third express synaptophysin, a neuroendocrine marker. This overlap can lead to initial misdiagnosis as carcinoma or a neuroendocrine tumor if the pathology workup is not comprehensive.11Modern Pathology. Anomalous Expression of Epithelial and Neuroendocrine Markers in Alveolar Rhabdomyosarcoma Molecular testing for PAX-FOXO1 fusions has become increasingly important not just for prognosis but for nailing down the diagnosis itself.
Standard Treatment
Treatment for RMS is multimodal, combining chemotherapy, surgery, and radiation in varying proportions depending on the tumor’s location, how much has spread, and its molecular profile. The backbone of chemotherapy has been remarkably consistent for decades: vincristine, actinomycin D, and cyclophosphamide (or ifosfamide in European protocols).12PubMed Central. Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma For high-risk patients, European trials have tested the addition of doxorubicin to the standard ifosfamide-vincristine-actinomycin regimen, seeking to improve response rates in those with incompletely resected or unfavorably located tumors.13The Lancet Oncology. Addition of doxorubicin to standard ifosfamide, vincristine, and actinomycin (IVA) chemotherapy for patients with high-risk rhabdomyosarcoma (EpSSG RMS 2005)
Surgery ranges from initial biopsy to complete tumor removal, depending on what is feasible without sacrificing critical organs. For tumors in the bladder or prostate, there has been a clear shift toward organ-sparing approaches. Cure rates for nonmetastatic bladder/prostate RMS have climbed from about 25% in the 1970s to over 80% in the 2000s, and much of that improvement has come from better integration of chemotherapy and radiation with less radical surgery.14PubMed. A review on surgical techniques and organ sparing procedures in bladder/prostate rhabdomyosarcoma
Radiation therapy plays a critical role, particularly for tumors that cannot be fully removed. Proton beam therapy has attracted growing interest for pediatric RMS because its physical properties allow doctors to deliver a high dose to the tumor while sparing more of the surrounding healthy tissue. For pelvic RMS specifically, proton therapy has shown similar local tumor control rates with less toxicity compared to older radiation techniques, and functional bladder preservation has been achieved in most patients treated this way.15PubMed. Outcomes Following Proton Therapy for Group III Pelvic Rhabdomyosarcoma The potential for reducing late side effects is especially important in young children whose developing tissues are vulnerable to radiation damage.16PubMed Central. Clinical Insight on Proton Therapy for Paediatric Rhabdomyosarcoma
When the Disease Comes Back
Relapse is one of the most feared scenarios in RMS, and the prognosis after it occurs depends heavily on the original tumor’s characteristics and the treatment already given. A small subset of patients with favorable initial features, such as those with botryoid (grape-like) RMS or low-stage embryonal tumors who were not previously treated with cyclophosphamide, have the best chance of long-term cure at relapse with multi-agent chemotherapy. Unfortunately, those patients represent the minority.17PubMed Central. Relapsed Rhabdomyosarcoma
A French study of patients who relapsed after initially nonmetastatic disease reported a five-year overall survival of 35% and a five-year progression-free survival of 26% from the time of first relapse. Second-line chemotherapy produced an objective response in about 59% of patients, but a striking finding was that no patient survived relapse without also receiving local treatment, meaning surgery or radiation or both on top of chemotherapy.18PubMed Central. Therapy and Outcomes of Patients with Relapsed Nonmetastatic Rhabdomyosarcoma That underscores how critical it is to achieve local control of the recurrent tumor, not just shrink it with drugs.
Why Adults with RMS Do Worse
RMS is overwhelmingly a pediatric disease, but it does occur in adults, and the outcomes are starkly different. An analysis of more than 2,600 patients found five-year overall survival rates of about 61% for children compared to 27% for adults. The gap was most dramatic in localized disease, where five-year survival was around 82% for children but only 47% for adults.19PubMed. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients
Several factors explain the discrepancy. Adult tumors are more likely to arise in unfavorable locations and to be classified as pleomorphic or “not otherwise specified,” subtypes that are uncommon in children and respond poorly to treatment. Adults have also historically been less likely to receive radiation, which appears to contribute independently to their worse outcomes.20International Journal of Radiation Oncology, Biology, Physics. Differences in Prognostic Factors and Treatment Impacts Between Pediatric and Adult Rhabdomyosarcoma Patients Separate analyses have confirmed that age over 50 is significantly associated with shorter overall survival even after accounting for other prognostic factors.21PubMed Central. Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients Part of this likely reflects biology: adult tumors simply tend to be molecularly different from their pediatric counterparts. But part of it also reflects the treatment ecosystem. Pediatric oncology centers have decades of refined, protocol-driven experience with RMS. Adults are more likely to be treated at general oncology centers where RMS is vanishingly rare and the treatment playbook is less established.
Genetic Predisposition
Most cases of RMS arise sporadically, without any known inherited cause. But a meaningful fraction occur in children who have an underlying genetic predisposition. Known syndromes that increase RMS risk include Li-Fraumeni syndrome (caused by inherited TP53 mutations), neurofibromatosis type 1, Noonan syndrome and other RASopathies, Costello syndrome, Beckwith-Wiedemann syndrome, constitutional mismatch repair deficiency, and DICER1-related conditions.22PubMed Central. Germline predisposition to genitourinary rhabdomyosarcoma Genetic counseling and germline testing are increasingly recommended for young RMS patients, particularly those with embryonal tumors of the genitourinary tract, where the prevalence of underlying genetic conditions tends to be higher.
Long-Term Side Effects of Treatment
Curing RMS often comes at a cost. The treatments themselves, particularly radiation to developing tissues, can produce lasting effects that become more apparent as survivors grow. A study of childhood cancer survivors showed substantially elevated risks for numerous conditions more than five years after diagnosis. Growth hormone deficiency was roughly 84 times more common than in siblings, and the need for medications to induce puberty was about 90 times more common. Congestive heart failure risk was elevated 43-fold, likely driven by anthracycline chemotherapy. Vision problems, thyroid dysfunction, seizures, and motor difficulties all remained elevated years after treatment ended.23PubMed. Long-term medical effects of childhood and adolescent rhabdomyosarcoma: a report from the childhood cancer survivor study
For head and neck RMS specifically, where tumors sit near the brain, eyes, and developing facial bones, radiation can cause facial disfigurement, cataracts, dental problems, hearing loss, and chronic sinus issues. One study found that over three-quarters of survivors had some degree of facial disfigurement, and about 30% had severe deformity, with younger age at treatment being a risk factor.24PubMed Central. Late toxicities of intensity-modulated radiation therapy for head and neck rhabdomyosarcoma These realities drive much of the research into more targeted therapies and gentler radiation techniques.
Psychosocial Impact on Survivors
The physical aftermath of treatment feeds directly into quality of life. Among head and neck RMS survivors, the majority report negative consequences on both appearance-related and health-related quality-of-life measures. In one multicenter study, 82% of survivors reported negative effects on appearance items, 81% on broader quality-of-life items, and 38% on facial function.25PubMed Central. Patient-reported outcomes in childhood head and neck rhabdomyosarcoma survivors and their relation to physician-graded adverse events A separate study found that survivors scored lower than population norms on school and work functioning and had a more negative self-image, with over half rating their appearance negatively on multiple items.26PubMed. Psychosocial well-being of long-term survivors of pediatric head-neck rhabdomyosarcoma
An interesting disconnect emerged in this research: physicians’ assessments of how bad a patient’s adverse events were did not correlate well with how the patients themselves rated their quality of life. Two survivors with similar clinical grades of disfigurement might report vastly different levels of distress. That gap highlights the importance of including patient-reported outcome measures in follow-up care rather than relying solely on clinician assessments.
Experimental Therapies on the Horizon
Despite decades of cooperative group trials, outcomes for advanced and metastatic RMS have not improved substantially since the 1970s. Five-year survival for children climbed from about 55% to 71% over the four IRS study periods, largely by refining treatment for lower-risk patients.27PubMed Central. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols For patients with widespread or relapsed disease, the chemotherapy backbone has essentially plateaued.28PubMed Central. Current and Future Treatment Strategies for Rhabdomyosarcoma
That has pushed researchers toward immunotherapy, and CAR-T cell therapy in particular has generated cautious optimism. CAR-T cells are a patient’s own immune cells, engineered in the lab to recognize and attack specific proteins on tumor surfaces. Several targets on RMS cells are being explored, including FGFR4, CD276, HER2, and PDGFR-α.29PubMed Central. CAR-T cell immunotherapy in rhabdomyosarcoma
Preclinical work has been promising. A study testing CAR-T cells designed to target both FGFR4 and CD276 simultaneously found that these dual-target cells had superior and longer-lasting anti-tumor activity compared to cells targeting FGFR4 alone, establishing proof-of-concept for this approach in RMS.30Nature Communications. CAR T-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma In the clinic, one published case report described a child with metastatic RMS who received HER2-targeted CAR-T cells in combination with the checkpoint inhibitor pembrolizumab. The child remained in disease remission 20 months after stopping CAR-T infusions.31Nature Communications. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma That is a single patient, not a clinical trial, so it is far too early to draw broad conclusions. But it illustrates the kind of durable response researchers are hoping to reproduce more systematically.
Other experimental approaches under investigation include small molecule inhibitors targeting the signaling pathways that RMS cells depend on, such as the RAS, PI3K/AKT/mTOR, and FGFR4 pathways, as well as oncolytic viruses and immune checkpoint inhibitors used alone or in combination with CAR-T cells. The challenge, as with many rare pediatric cancers, is that the small number of eligible patients makes large randomized trials difficult to conduct, slowing the pace at which promising laboratory findings translate into approved treatments.
Invasion and Metastasis Pathways
Understanding how RMS spreads has been an active area of research. Fusion-positive RMS relies heavily on the PAX3-FOXO1 fusion protein itself to drive invasion, while fusion-negative tumors use a constellation of signaling pathways including those driven by IGF, RAS, cMET, FGFR4, and PDGFR. Both subtypes appear to use some of these pathways in common, which may partially explain why both can be aggressive despite having different root molecular defects.32PubMed Central. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium More recent work has identified that RMS cells also release exosomes, tiny membrane-bound packages carrying proteins and small RNAs, that may prepare distant tissues for metastatic colonization. This paracrine communication between the tumor and its surroundings adds another layer of complexity to an already challenging disease.